Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Pawtucket, Rhode Island Clinical Trials

A listing of Pawtucket, Rhode Island clinical trials actively recruiting patient volunteers.

RESULTS

Found (48) clinical trials

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

The primary objective of this study is to evaluate the safety and tolerability of lucinactant for inhalation, administered as an aerosolized dose in up to four escalating doses to preterm neonates 26 to 28 weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome ...

Phase

3.57 miles

Learn More »

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure ...

Phase

3.57 miles

Learn More »

BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Neoadjuvant therapy is given to breast cancer patients whose cancers are relatively large or have spread to lymph nodes or both. The primary goal of this treatment is to prevent the cancer from coming back (recurring) elsewhere in the body, but if it makes the cancer in the breast and ...

Phase

3.57 miles

Learn More »

Olaparib and Cediranib Maleate in Treating Patients With Recurrent Refractory or Metastatic Endometrial Cancer

PRIMARY OBJECTIVES: I. To compare the efficacy of single-agent olaparib and the combination of olaparib and cediranib (and potentially other combination arms that may be added by subsequent amendment) versus single agent cediranib as measured by progression free survival (PFS), in patients with recurrent, persistent or metastatic endometrial cancer. SECONDARY ...

Phase

3.57 miles

Learn More »

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

The study will evaluate the safety and efficacy of AV-101.

Phase

3.72 miles

Learn More »

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Phase

3.72 miles

Learn More »

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

Congenital cytomegalovirus (CMV) infection is the most frequent known viral cause of mental retardation, and is the leading non-genetic cause of sensorineural hearing loss in many countries including the United States. This is a Phase II international, multi-center, double-blind, placebo-controlled evaluation of 6 weeks of oral valganciclovir treatment or 6 ...

Phase

4.0 miles

Learn More »

The purpose of this study is to evaluate the efficacy of 24 weeks of treatment with INCB018424 cream in subjects with vitiligo.

Phase

4.0 miles

Learn More »

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

PRIMARY OBJECTIVES: I. To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. II. To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can ...

Phase

4.0 miles

Learn More »

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.

Phase

4.0 miles

Learn More »